250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 5 Biotech Startup Investors in Isle of Man in September 2024

A list of 5 angel investors and VC (Venture Capital) funds that invest in Biotech startups based in Isle of man. We rank investors based on the number of investments they made in Biotech companies from Isle of man. We update this investor list every month.

Top 5 Biotech Startup Investors in Isle of Man in September 2024

Investor Biotech Isle of Man investments
Jim Mellon 1
Andrew Banks 1
Juvenescence 1
Greg Bailey 1
Foresite Capital 1
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
Jim Mellon Angel
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
Show more
Investment focus
  • Biotechnology, Health Care, Food and Beverage
  • Series A, Seed, Funding Round
  • United States, United Kingdom, Israel
Portfolio highlights
  • Voxia — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
  • Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
  • The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.
Andrew Banks Angel · London, England, United Kingdom
Andrew Banks - Chairman and Co-Founder @ ABRY Partners
Show more
Investment focus
  • Biopharma, Biotechnology, Pharmaceutical
  • Seed
  • Isle of Man
Portfolio highlights
  • Juvenescence — Juvenescence is extending healthy human lifespan through aging research, development of therapies to counter age-related diseases & our ketone ester drink, Metabolic Switch.
Juvenescence VC Fund · Douglas, NA - Isle of Man, Isle of Man
Juvenescence is extending healthy human lifespan through aging research, development of therapies to counter age-related diseases & our ketone ester drink, Metabolic Switch.
Show more
Investment focus
  • Biotechnology, Pharmaceutical, Health Care
  • Funding Round, Series A, Debt Financing
  • United States, Hong Kong, Isle of Man
Portfolio highlights
  • LyGenesis — LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).
  • MDI Therapeutics — MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments usingclinical biomarkers.
  • Souvien Therapeutics — Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.
Greg Bailey Angel · London, England, United Kingdom
Dr. Gregory H. Bailey is a Managing Partner at Palantir Group, Inc. Dr. Bailey is the Co-founder of Ascent Healthcare Solutions; VirnetX Inc. (AMEX:VHC) and Duramedic Inc. He was also the initial public financier and an independent director of Medivation, Inc. (NASDAQ:MDVN), from 2005 to December 2012. Dr. Bailey served as the Managing Director andco-Head of Life Sciences at MDB Capital Group LLC from May 2004 to January 2007. Previously he served as Life Sciences Analyst at Participating Capital, Corp. He has served on the board of directors of multiple public companies. Dr. Bailey has Medical Doctorate from the University of Western Ontario and practiced medicine as an emergency physician for ten years.
Show more
Investment focus
  • Biotechnology, Pharmaceutical, Medical
  • Seed, Series A, Funding Round
  • United States, Isle of Man
Portfolio highlights
  • Juvenescence — Juvenescence is extending healthy human lifespan through aging research, development of therapies to counter age-related diseases & our ketone ester drink, Metabolic Switch.
  • Bristol-Myers Squibb — Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
  • Biohaven Pharmaceutical — Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipelineproducts include BHV3000-301, BHV3000-302, BHV3000-303, and others.
Foresite Capital VC Fund · San Francisco, California, United States · 8 investments in the past 12 months
We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series C, Series A
  • United States, United Kingdom, Australia
Portfolio highlights
  • Spear Bio — Successive Proximity Extension Amplification Reaction (SPEAR) technology from Spear Bio enables ultra-sensitive biomarker detection using ultra-small samples.
  • Element Biosciences — Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. We are developing a modular and high-performing DNA sequencing platform that will deliver high quality data, workflow flexibility, and make next-generation sequencing technology more accessible. Our proprietaryapproach to improve the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation and biochemistry to drastically decrease the run cost and capital cost while delivering high sequencing data quality.
  • Foresight Diagnostics — Breakthrough cancer diagnostics. Next-level clinical outcomes. Foresight Diagnostics develops and delivers innovative diagnostic tests that combine precisio ...
Investors by industry
Investors by country
Investors in Isle of Man by industry